Epigenetic Treatment of Hematopoietic Malignancies: In Vivo Targets of Demethylating Agents
- 1 October 2005
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 32 (5) , 511-520
- https://doi.org/10.1053/j.seminoncol.2005.07.024
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Azacitidine Induces Demethylation of the Epstein-Barr Virus Genome in TumorsJournal of Clinical Oncology, 2004
- Expression levels of DNA methyltransferase genes do not correlate with p15INK4B gene methylation in myelodysplastic syndromesLeukemia, 2003
- Gene silencing of the p15/INK4B cell-cycle inhibitor by hypermethylation: an early or later epigenetic alteration in myelodysplastic syndromes?Leukemia, 2003
- 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?Blood, 2003
- Frequent expression of HAGE in presentation chronic myeloid leukaemiasLeukemia, 2002
- MAGE-1 gene is expressed in T-cell leukemiaInternational Journal of Cancer, 1996
- Expression of MAGE genes in primary and metastatic cutaneous melanomaInternational Journal of Cancer, 1995
- Expression of the MAGE gene family in human lymphocytic leukemiaCancer Immunology, Immunotherapy, 1995
- Structure, chromosomal localization, and expression of 12 genes of the MAGE familyImmunogenetics, 1994
- 5-Azacytidine Selectively Increases γ-Globin Synthesis in a Patient with β+ThalassemiaNew England Journal of Medicine, 1982